keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer neoadjuvant treatment

keyword
https://www.readbyqxmd.com/read/27905097/novel-biomarkers-in-primary-breast-core-biopsies-to-predict-poor-response-to-neoadjuvant-chemotherapy-and-appearance-of-metastases
#1
Anna Novell, Serafin Morales, Joan Valls, Maria José Panadés, Antonieta Salud, Edelmiro Iglesias, Felip Vilardell, Xavier Matias-Guiu, Antonio Llombart-Cussac
Drug resistance has been one of the major obstacles limiting the success of cancer chemotherapy. In two thirds of breast cancer patients, large (>1cm) residual tumors are present after neoadjuvant chemotherapy (NCT). The residual tumor and involved nodes have been indicators of relapse and survival very important in breast cancer. The goal of this preliminary study was to assess the predictive significance of a panel of molecular biomarkers, related with the response to treatment or drug resistance to NCT, as determined on the diagnostic tumor...
December 1, 2016: Histology and Histopathology
https://www.readbyqxmd.com/read/27903675/a-pam50-based-chemo-endocrine-score-for-hormone-receptor-positive-breast-cancer-with-an-intermediate-risk-of-relapse
#2
Aleix Prat, Ana Lluch, Arran K Turnbull, Anita K Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montse Muñoz, Laia Paré, Joel S Parker, Nuria Ribelles, Begona Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva M Carrasco, Miguel Martín, J Michael Dixon, Charles M Perou, Emilio Alba
PURPOSE: Hormone receptor-positive (HR+) breast cancer is clinically and biologically heterogeneous and subgroups with different prognostic and treatment sensitivities need to be identified. EXPERIMENTAL DESIGN: Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR+/HER2- disease randomized to neoadjuvant multi-agent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based Chemo-Endocrine Score (CES)...
November 30, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27903276/accurate-prediction-of-response-to-endocrine-therapy-in-breast-cancer-patients-current-and-future-biomarkers
#3
REVIEW
Cigdem Selli, J Michael Dixon, Andrew H Sims
Approximately 70% of patients have breast cancers that are oestrogen receptor alpha positive (ER+) and are therefore candidates for endocrine treatment. Many of these patients relapse in the years during or following completion of adjuvant endocrine therapy. Thus, many ER+ cancers have primary resistance or develop resistance to endocrine therapy during treatment. Recent improvements in our understanding of how tumours evolve during treatment with endocrine agents have identified both changes in gene expression and mutational profiles, in the primary cancer as well as in circulating tumour cells...
December 1, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27889596/using-ultrasound-and-palpation-for-predicting-axillary-lymph-node-status-following-neoadjuvant-chemotherapy-results-from-the-multi-center-sentina-trial
#4
Lukas Schwentner, Gisela Helms, Valentina Nekljudova, Beyhan Ataseven, Ingo Bauerfeind, Nina Ditsch, Tanja Fehm, Barbara Fleige, Maik Hauschild, J Heil, Sherko Kümmel, Anette Lebeau, Sabine Schmatloch, Peter Schrenk, Anette Staebler, Sibylle Loibl, Michael Untch, Gunter Von Minckwitz, Cornelia Liedtke, Thorsten Kühn
BACKGROUND: With the growing importance of neoadjuvant systemic therapy (NST) the assessment of post neoadjuvant axillary status is of increasing importance especially in patients who presented initially with suspicious nodes (cN1). This study aims to investigate the predictive value of palpation and axillary ultrasound of formerly cN1 patients following NST. PATIENTS AND METHODS: The SENTINA trial (SENTinel NeoAdjuvant) is a 4-arm prospective multicenter study designed to evaluate the role of sentinel node biopsy (SLNB) in the context of neoadjuvant systemic treatment (NST) of breast cancer patients...
November 24, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27889595/is-there-a-role-for-salvage-radiotherapy-in-locally-advanced-breast-cancer-refractory-to-neoadjuvant-chemotherapy
#5
R C Coelho, F M L Da Silva, I M L Do Carmo, B V Bonaccorsi, S M Hahn, L D Faroni
INTRODUCTION: Locally advanced breast cancer (LABC) is a major problem, especially in developing countries. The standard treatment for LABC is neoadjuvant chemotherapy, with or without anti-Her2 therapy, followed by surgery, radiotherapy, and adjuvant systemic treatment if appropriate. However, there are few data in the literature addressing alternatives when neoadjuvant chemotherapy fails to reduce the tumour for surgery. MATERIALS AND METHODS: We conducted a retrospective study including all patients who had non-metastatic LABC treated with neoadjuvant chemotherapy and who were not eligible for surgical resection; these patients were submitted to salvage radiotherapy (RTX) between January 2000 and December 2012 at the Brazilian National Cancer Institute...
November 24, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27885439/weekly-paclitaxel-plus-carboplatin-with-or-without-trastuzumab-as-neoadjuvant-chemotherapy-for-her2-positive-breast-cancer-loss-of-her2-amplification-and-its-impact-on-response-and-prognosis
#6
Ruo-Xi Wang, Sheng Chen, Xi Jin, Can-Ming Chen, Zhi-Ming Shao
PURPOSE: Neoadjuvant chemotherapy (NCT) plus anti-HER2 agents are the standard of care for locally advanced HER2-positive breast cancer. The aim of this study was to evaluate the prevalence and prognostic impact of HER2 loss in patients with HER2-positive disease treated with neoadjuvant therapy with or without trastuzumab. METHODS: 549 consecutive HER2-positive patients were included in this study. 379 patients were treated with paclitaxel, carboplatin, and trastuzumab (PCH cohort) and 170 were treated with paclitaxel and carboplatin only (PC cohort)...
November 24, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27877006/early-prediction-of-pathological-outcomes-to-neoadjuvant-chemotherapy-in-breast-cancer-patients-using-automated-breast-ultrasound
#7
Xinguang Wang, Ling Huo, Yingjian He, Zhaoqing Fan, Tianfeng Wang, Yuntao Xie, Jinfeng Li, Tao Ouyang
OBJECTIVE: Early assessment of response to neoadjuvant chemotherapy (NAC) for breast cancer allows therapy to be individualized. The optimal assessment method has not been established. We investigated the accuracy of automated breast ultrasound (ABUS) to predict pathological outcomes after NAC. METHODS: A total of 290 breast cancer patients were eligible for this study. Tumor response after 2 cycles of chemotherapy was assessed using the product change of two largest perpendicular diameters (PC) or the longest diameter change (LDC)...
October 2016: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/27875106/neoadjuvant-systemic-therapy-in-breast-cancer-association-of-contrast-enhanced-mr-imaging-findings-diffusion-weighted-imaging-findings-and-tumor-subtype-with-tumor-response
#8
Gorane Santamaría, Xavier Bargalló, Pedro Luis Fernández, Blanca Farrús, Xavier Caparrós, Martin Velasco
Purpose To investigate the performance of tumor subtype and various magnetic resonance (MR) imaging parameters in the assessment of tumor response to neoadjuvant systemic therapy (NST) in patients with breast cancer and to outline a model of pathologic response, considering pathologic complete response (pCR) as the complete absence of any residual invasive cancer or ductal carcinoma in situ (DCIS). Materials and Methods This was an institutional review board-approved retrospective study, with waiver of the need to obtain informed consent...
November 22, 2016: Radiology
https://www.readbyqxmd.com/read/27872526/progesterone-receptors-pathological-complete-response-and-early-outcome-for-locally-advanced-breast-cancer-a-single-centre-study-pplb-01
#9
Sanjit Agrawal, Lalit Banswal, Animesh Saha, Indu Arun, Soumitra Shankar Datta, Sanjoy Chatterjee, Rosina Ahmed
Neoadjuvant chemotherapy (NACT) for locally advanced breast cancer (LABC), apart from increasing breast conservation rates, also provides an opportunity to assess tumour response to chemotherapy, with Pathological Complete Response (pCR) described as an independent prognostic factor and a surrogate marker for better outcome and survival. Our primary aim was to identify clinical and pathological factors associated with pCR following NACT in patients with LABC treated at our institution. Our secondary aim was to analyze the impact of pCR and associated factors on disease free survival (DFS) and overall survival (OS)...
December 2016: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27868411/-efficacy-of-neoadjuvant-chemotherapy-combined-with-bevacizumab-versus-neoadjuvant-chemotherapy-alone-for-her2-negative-breast-cancer-a-meta-analysis-of-randomized-controlled-clinical-trials
#10
Rui Han, Guanying Wang, Yujiao Zhang, Xinhan Zhao
Objective: To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer.Methods: We searched PubMed, the Cochrane Library, Web of Science, CNKI, Wanfang Database and the abstracts of major international conferences in recent 5 years to identify prospective randomized controlled clinical trials that met the inclusion and exclusion criteria. Study selection and analyses were undertaken according to the Cochrane Handbook...
May 25, 2016: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/27866067/escalating-and-de-escalating-treatment-in-her2-positive-early-breast-cancer
#11
REVIEW
Heikki Joensuu
The current standard adjuvant systemic treatment of early HER2-positive breast cancer consists of chemotherapy plus 12months of trastuzumab, with or without endocrine therapy. Several trials have investigated modifications of the standard treatment that are shorter and less resource-demanding (de-escalation) or regimens that aim at dual HER2 inhibition or include longer than 12months of HER2-targeted treatment (escalation). Seven randomized trials investigate shorter than 12months of trastuzumab treatment duration...
November 10, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27856630/a-prospective-clinical-trial-of-18f-fluciclovine-pet-ct-neoadjuvant-therapy-response-in-invasive-ductal-and-invasive-lobular-breast-cancers
#12
Gary A Ulaner, Debra Goldman, Adriana Corben, Serge Lyashchenko, Mithat Gonen, Jason Lewis, Maura Dickler
: Fluorine-18-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid ((18)F-Fluciclovine) is a leucine analog radiotracer that depicts amino acid transport into cells. (18)F-Fluciclovine PET/CT visualizes malignancy including prostate cancer, invasive ductal breast cancer (IDC) and invasive lobular breast cancers (ILC). It has not been shown whether changes in (18)F-Fluciclovine avidity reflect changes in tumor burden resulting from treatment. This prospective clinical trial evaluates changes in (18)F-Fluciclovine-avidity compared to breast cancer therapy response, as determined by residual tumor burden on pathology...
November 17, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27853985/a-definition-for-aggressive-disease-in-patients-with-her-2-negative-metastatic-breast-cancer-an-expert-consensus-of-the-spanish-society-of-medical-oncology-seom
#13
REVIEW
A González, A Lluch, E Aba, J Albanell, A Antón, I Álvarez, F Ayala, A Barnadas, L Calvo, E Ciruelos, J Cortés, J de la Haba, J M López-Vega, E Martínez, M Muñoz, I Peláez, A Redondo, Á Rodríguez, C A Rodríguez, A Ruíz, A Llombart
PURPOSE: To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology. METHODS: A panel of 21 breast cancer experts from the Spanish Society of Medical Oncology agreed upon a survey which comprised 47 questions that were grouped into three sections: relevance for defining aggressive disease, aggressive disease criteria and therapeutic goals. Answers were rated using a 9-point Likert scale of relevance or agreement...
November 16, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27853488/changes-of-t2-relaxation-time-from-neoadjuvant-chemotherapy-in-breast-cancer-lesions
#14
Li Liu, Bo Yin, Dao Ying Geng, Yi Ping Lu, Wei Jun Peng
BACKGROUND: Neoadjuvant chemotherapy (NAC) is generally an effective method of reducing locally advanced malignant breast lesions before surgery; assessing the tumor response to NAC is crucial for patient management. T2 relaxation times can reflect biological state of lesions, may prove useful to assess the response to NAC. OBJECTIVES: To investigate the lesion T2 relaxation times change in breast cancer neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: In total, 26 patients underwent NAC...
July 2016: Iranian Journal of Radiology: a Quarterly Journal Published By the Iranian Radiological Society
https://www.readbyqxmd.com/read/27825710/breast-conservation-following-neoadjuvant-therapy-for-breast-cancer-in-the-modern-era-are-we-losing-the-opportunity
#15
REVIEW
C Criscitiello, G Curigliano, H J Burstein, S Wong, A Esposito, G Viale, M Giuliano, U Veronesi, M Santangelo, M Golshan
The main rationale for neoadjuvant therapy for breast cancer is to provide effective systemic treatment while surgically down-staging the cancer. This down-staging was initially to convert inoperable patients to operable and later to increase rates of breast conservation in patients initially deemed mastectomy only candidates. Unexpectedly, in recent neoadjuvant trials lower rates of breast conservation have been observed than in past decades, despite remarkable advances in systemic therapies, which have increased pathologic complete response rates...
October 29, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27822368/primary-surgical-treatment-of-locally-advanced-breast-cancer-in-low-resource-settings
#16
Elroy Patrick Weledji, Felix Adolphe Elong
•Optimum management of locally advanced breast cancer is multidisciplinary.•Neoadjuvant chemotherapy is mainstay of management.•Primary surgical treatment may be acceptable in selected patients.
December 2016: Annals of Medicine and Surgery
https://www.readbyqxmd.com/read/27821323/combination-of-shear-wave-elastography-and-ki-67-index-as-a-novel-predictive-modality-for-the-pathological-response-to-neoadjuvant-chemotherapy-in-patients-with-invasive-breast-cancer
#17
Yan Ma, Shuo Zhang, Li Zang, Jing Li, Jianyi Li, Ye Kang, Weidong Ren
PURPOSE: This study evaluated shear wave elastography (SWE) and SWE combined with the Ki-67 index as novel predictive modalities for the pathological response of invasive breast cancer to neoadjuvant chemotherapy (NAC). METHODS: The prospective study recruited 66 eligible patients from July 2014 to November 2015. Tumour stiffness, which corresponds with tumour progression and invasiveness, was assessed by quantitative SWE 1 d before biopsy (time point t0, elasticity E0), 1 d before next NAC cycle (t1-t5, E1-E5), and 1 d before surgery (t6, E6)...
November 4, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27817858/-systemic-neoadjuvant-therapy-of-luminal-breast-cancer-in-2016
#18
REVIEW
Paul H Cottu
Neoadjuvant systemic therapies have been extensively evaluated in luminal breast cancer. Conventional cytotoxic chemotherapy increases breast conservation rate, albeit with a low level of complete pathological response of uncertain clinical significance. Endocrine therapies allow similar clinical results with much less side effects. Biological criteria of response to endocrine therapies are still being defined. The neoadjuvant setting must be used for early development of new compounds and to further document biological mechanisms of sensitivity and resistance to treatments...
November 3, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27812689/association-of-polymorphisms-in-fcgr2a-and-fcgr3a-with-degree-of-trastuzumab-benefit-in-the-adjuvant-treatment-of-erbb2-her2-positive-breast-cancer-analysis-of-the-nsabp-b-31-trial
#19
Patrick G Gavin, Nan Song, S Rim Kim, Corey Lipchik, Nicole L Johnson, Hanna Bandos, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas, Sandra M Swain, D Lawrence Wickerham, Charles E Geyer, Jong-Hyeon Jeong, Joseph P Costantino, Norman Wolmark, Soonmyung Paik, Kay L Pogue-Geile
Importance: Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2-positive breast cancer, by modulating antibody-dependent cell-mediated cytotoxic effects. Objective: To evaluate the effect of FCGR2A and FCGR3A polymorphisms on trastuzumab efficacy in the adjuvant treatment of ERBB2/HER2-positive breast cancer...
November 3, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27810698/intraoperative-assessment-of-sentinel-lymph-node-by-one-step-nucleic-acid-amplification-in-breast-cancer-patients-after-neoadjuvant-treatment-reduces-the-need-for-a-second-surgery-for-axillary-lymph-node-dissection
#20
Martin Espinosa-Bravo, Joaquin Navarro-Cecilia, Manuel Ramos Boyero, Sebastian Diaz-Botero, Basilio Dueñas Rodríguez, Carolina Luque López, Teresa Ramos Grande, Ricardo Ruano Perez, Vicente Peg, Isabel T Rubio
PURPOSE: Sentinel lymph node (SLN) biopsy has been shown to be both accurate and feasible for women who receive neoadjuvant chemotherapy (NAC). Intraoperative assessment of SLN by frozen sections can produce false negative results. The aim of this study was to compare two different techniques of intraoperative assessment of SLN in breast cancer patients treated with NAC: frozen section (FS) and molecular assay (OSNA). METHODS: A multicenter cohort of 320 consecutive breast cancer patients treated with NAC between 2010 and 2014 was analyzed...
October 28, 2016: Breast: Official Journal of the European Society of Mastology
keyword
keyword
105931
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"